A Study of Viracept in AIDS Patients With Mycobacterium Avium Complex Disease (MAC)
Launched by AGOURON PHARMACEUTICALS · Aug 30, 2001
Trial Information
Current as of March 20, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- • Inclusion Criteria
- Patients must have:
- • HIV infection
- • New diagnosis of MAC bacteremia and \< 7 days of therapy.
- Prior Medication:
- Allowed:
- • Patients no more than 7 days of therapy for MAC disease.
- • Exclusion Criteria
- Prior Medication:
- Excluded:
- • Prior therapy (or less than 2 weeks) with protease inhibitors other than saquinavir.
About Agouron Pharmaceuticals
Agouron Pharmaceuticals is a biopharmaceutical company dedicated to advancing innovative therapies for the treatment of serious medical conditions. With a strong focus on research and development, Agouron leverages cutting-edge science and technology to discover and optimize novel drug candidates. The company is committed to improving patient outcomes through rigorous clinical trials and collaborations with healthcare professionals. By prioritizing safety and efficacy, Agouron aims to deliver transformative solutions that address unmet medical needs and enhance the quality of life for patients around the world.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Chicago, Illinois, United States
Torrance, California, United States
San Diego, California, United States
Houston, Texas, United States
Boston, Massachusetts, United States
People applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Discussion 0
Related articles
Similar Trials